A new look at back pain treatment in light of the latest ESCEO guidelines
https://doi.org/10.14412/2074-2711-2020-6-90-95
Abstract
Chronic pain (CP) is still one of the urgent problems of modern medicine. The paper provides a review of the main pharmacotherapeutic approaches from the standpoint of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) guidelines. When preparing this material, the authors have analyzed the publications available in the resources: PubMed, EMBASE, Cochrane, and еLIBRARY. The paper presents the main pathogenetic mechanisms of pain syndrome development in osteoarthritis (OA), including synovial inflammation and associated immune disorders. It considers the types of development of pain syndrome and the main prognostic outcomes according the mechanism of pain, providing a rationale for the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or chondroprotectors (CPs). In accordance with the ESCEO guidelines, it is noted that when starting OA therapy, CPs should be considered as the first step (in their long-term prescription and pharmaceutical quality), then NSAIDs should be added (topically), then (if ineffective) orally, by excluding patients with hip OA. It is known that the intramuscular administration of CPs (chondroitin sulfate (CS) in particular) can increase their bioavailability. The use of glucosamine sulfate (GS) is recommended for patients over 60 years of age. According to the recommendations of the 2019 ESCEO experts, CS and GS should be used as a disease-modifying OA drug from the first step and at all subsequent stages.
Supporting agencies: Publication of this article has been supported by Sotex PharmFirma
About the Authors
O. A. Shavlovskaya
Mental Health Research Center
Russian Federation
Russian Federation
Olga Aleksandrovna Shavlovskaya
34A, Kashirskoe Shosse, Moscow 115522
I. A. Zolotovskaya
Samara State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
89, Chapaevskaya St., Samara 443099
Yu. A. Prokofyeva
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia;
S.I. Spasokukotsky Moscow City Clinical Hospital, Moscow Healthcare Department
Russian Federation
Russian Federation
20, Delegatskaya St., Build. 1, Moscow 127473,
21, Vuchetich St., Moscow 127206
References
1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009. Epub 2005 Aug 10.
2. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. BMJ. 2015 Feb 18;350:h444. doi: 10.1136/bmj.h444
3. Thiem U, Lamsfus R, GЯnther S, et al. Prevalence of self-reported pain, joint complaints and knee or hip complaints in adults aged ≥ 40 years: a cross-sectional survey in Herne, Germany. PLoS One. 2013 Apr 30;8(4):e60753. doi: 10.1371/journal.pone.0060753. Print 2013.
4. Murphy R, Carr A. Management of shoulder pain in general practice. InnovAiT: Educat Inspirat General Pract. 2009;2(7):402-7. doi: 10.1093/innovait/inp044
5. Murphy R, Carr A. Shoulder pain. BMJ Clin Evid. 2010 Jul 22;2010:1107. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21418673 (accessed 26.10.2020).
6. Becker HH, Redaelli M, Strauch K, et al. Low back pain in primary care: costs of care and prediction of future health care utilization. Spine (Phila Pa 1976). 2010 Aug 15;35(18):1714-20. doi: 10.1097/brs.0b013e3181cd656f
7. Tegner H, Frederiksen P, Esbensen BA, et al. Neurophysiological pain education for patients with chronic low back pain: a systematic review and meta-analysis. Clin J Pain. 2018;34(8):778- 86. doi: 10.1097/ajp.0000000000000594
8. McIntosh G, Hall H. Low back pain (acute). BMJ Clin Evid. 2011;1102. Available from: http://www.biomedsearch.com/nih/Low-backpain-acute/21549023.html (accessed 26.10.2020).
9. Shavlovskaya OA, Zolotovskaya IA, Prokofyeva YuS. Anti-inflammatory and antiaging effects of chondroitin sulfate. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):111-6. doi: 10.14412/2074-2711-2020-5-111-116 (In Russ.).
10. Martel-Pelletier J, Farran A, Montell E, et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules. 2015 Mar 6;20(3):4277-89. doi: 10.3390/molecules20034277
11. Jones MR, Ehrhardt KP, Ripoll JG, et al. Pain in the elderly. Curr Pain Headache Rep. 2016;20(4):23. doi: 10.1007/s11916-016-0551-2
12. Parfenov VA, Yakhno N.N, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4- 11. doi: 10.14412/2074-2711-2018-2-4-11 (In Russ.).
13. Wilkie R, Tajar A, McBeth J. The onset of widespread musculoskeletal pain is associated with a decrease in healthy ageing in older people: a population-based prospective study. PLoS One. 2013;8(3):e59858. doi: 10.1371/journal.pone.0059858. Epub 2013 Mar 29.
14. Leung Y-Y, Teo SL, Chua MB, et al. Living arrangements, social networks and onset or progression of pain among older adults in Singapore. Geriatr Gerontol Int. 2016;16(6):693- 700. doi: 10.1111/ggi.12539.Epub 2015 Jun 16.
15. Van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaest. 2013;111(1):13-8. doi: 10.1093/bja/aet123
16. Karateev AE, Nasonov EL, Ivashkin VT, et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl.1):1-29. doi: 10.14412/1995-4484-2018-1-29 (In Russ.).
17. Naumov AV, Tkacheva ON. Use of a glycosamine sulfate for patients with osteoarthritis and a comorbidity with high risk of the side effects from NSAIDS. Terapevticheskiy arkhiv = Therapeutic Archive. 2018;(5):81-7. doi: 10.26442/terarkh201890581-87 (In Russ.).
18. Shavlovskaya OA. Chondroprotectors: a range of application in general somatic practice. Terapevticheskiy arkhiv = Therapeutic Archive. 2017;89(5):98-104. doi: 10.17116/terarkh201789598-104 (In Russ.).
19. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55. doi: 10.1136/ard.2003.011742
20. Dougados M. Symptomatic slow-acting drugs for osteoarthritis: what are the facts? Joint Bone Spine. 2006;73(6):606-9. doi: 10.1016/j.jbspin.2006.09.008. Epub 2006 Oct 11.
21. Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. doi: 10.1136/annrheumdis-2017-212662. Epub 2018 May 3.
22. Bruyere O, Cooper C, Pelletier J, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.
23. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008
24. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology / Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62. doi: 10.1002/acr.24131. Epub 2020 Jan 6.
25. Parfenov VA, Yakhno NN, Davydov OS, et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(Suppl. 2):7-16. doi: 10.14412/2074-2711-2019-2S-7-16 (In Russ.).
26. Zolotovskaya IA, Davydkin IL. A antiresorptive-cytokine effects of chondroprotective therapy in patients with lower back pain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(4):65-71. doi: 10.17116/jnevro202012004165 (In Russ.).
27. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially omega-3 fatty acids. Int J Rheumatol. 2011;2011:969012. doi: 10.1155/2011/969012. Epub 2011 Aug 2.
28. Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2017;30(2):111- 7. doi: 10.1007/s40520-017-0861-1
29. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomized, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2015;75:37- 44. doi: 10.1136/annrheumdis-2014-206792
30. Singh JA, Noorbaloochi S, MacDonald R, et al. The Cochrane Collaboration Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015 Jan 28;1:CD005614. doi: 10.1002/14651858.cd005614.pub2
31. Honvo G, Bruyere O, Geerinck A, et al. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebocontrolled trials. Adv Ther. 2019;36(5):1085-99. doi: 10.1007/s12325-019-00921-w
32. Shang Q, Yin Y, Zhu L, et al. Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. Int J Biol Macromol. 2016;86:112-8. doi: 10.1016/j.ijbiomac.2016.01.055
33. Identification number of the CI protocol of the Ministry of Health of the Russian Federation: KI/1216-1 «Double-blind, placebo-controlled, randomized study of the efficacy and safety of Chondrogard®, solution for intramuscular injection 100 mg / ml (ZAO PharmFirma Sotex, Russia) in patients with gonarthrosis». Available from: http://grls.rosminzdrav.ru/ (accessed 10.26.2020) (In Russ.).
34. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011
35. Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018;320(24):2564-79. doi: 10.1001/jama.2018.19319
36. Simental-Mendia M, Sanchez-Garcia A, Vilchez-Cavazos F, et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and metaanalysis of randomized placebo-controlled trials. Rheumatol Int. 2018;38(8):1413-28. doi: 10.1007/s00296-018-4077-2
37. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012;4(3):167-80. doi: 10.1177/1759720x12437753
38. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18:476-99. doi: 10.1016/j.joca.2010.01.013
39. Chiusaroli R, Piepoli T, Zanelli T, et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011;2011:939265. doi: 10.1155/2011/939265. Epub 2011 Oct 9
40. Identification number of the CI protocol of the Ministry of Health of the Russian Federation: KI / 0113-1 «Randomized, blind, multicenter, placebo-controlled clinical study to study the efficacy and safety of Sustagard-Arthro, solution for intramuscular injection in patients with osteoarthritis of the knee joint (gonarthrosis) in parallel groups». Available from: http://grls.rosminzdrav.ru/ (accessed 10.26.2020) (In Russ.).
41. Bruyere O, Cooper C, Pelletier J-P, et al. A consensus statement on the european society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4):S3-11. doi: 10.1016/j.semarthrit.2015.11.010
42. Sobal G, Dorotka R, Menzel J, et al. Uptake studies with chondrotropic 99mTcchondroitin sulfate in articular cartilage. Implications for imaging osteoarthritis in the knee. Nucl Med Biol. 2013;40(8):1013-7. doi: 10.1016/j.nucmedbio.2013.07.007
43. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthr Cartil. 2003;11(6):433- 41. doi: 10.1016/s1063-4584(03)00051-7
44. Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci. 2007;96:3168-80. doi: 10.1002/jps.20997
45. Alekseeva LI, Sharapova EP, Kashevarova NG, et al. Comparative study of the efficacy and safety of Chondroguard® during its combined (intra-articular and intramuscular) and intramuscular injection in patients with kneeosteoarthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(2):44-9. doi: 10.14412/1996-7012-2018-2-44-49 (In Russ.).
46. Naumov AV, Sharov MN, Khovasova NO, et al. Results of the intermittent regimen of initial pain therapy with chondroitin sulfate and glucosamine sulfate for patients with osteoarthritis, back pain and comorbidity. RMJ. 2018;4(II):47-54. Available from: https://www.rmj.ru/articles/nevrologiya/Rezuly taty_primeneniya_intermittiruyuschey_shemy_parenteralynogo_vvedeniya_hondroitina_sulyfata_i_glyukozamina_sulyfata_v_startterapii_hronicheskoy_boli_v_sustavah_i_spine_ u_komorbidnyh_pacientov/ (accessed 26.10.2020) (In Russ).
47. Alekseeva LI. Сlinical guidelines update on the treatment of patients with osteoarthritis in 2019. RMJ. 2019;27(4):2-6. Available from: https://www.elibrary.ru/item.asp?id=38502084 (accessed 26.10.2020). (In Russ.).
48. Lila AM, Alekseeva LI, Taskina EA. Modern approaches to osteoarthritis therapy taking into account updated international guidelines. RMZh. Meditsinskoye obozreniye = RMJ. Medical Review. 2019;11(2):48052. Available from: https://www.rmj.ru/articles/revmatologiya/Sovremennye_podhody_k_terapii_osteoartrita_s_uchetom_obnovlennyh_meghdunarodnyh_rekomendaciy/ (accessed 26.10.2020) (In Russ.).
49. Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21. doi: 10.14412/1996-7012-2019-2-9-21 (In Russ.).
50. Shavlovskaya OA, Romanov ID, Artemenko AR. Combination of injection chondroprotectors for chronic non-specific back pains and osteoarthritis. RMZh. Meditsinskoye obozreniye = RMJ. Medical Review. 2019;11(1):6-12. Available from: https://www.rmj.ru/articles/bolevoy_sindrom/Lechenie_nespecificheskoy_boli_v_spine_i_osteoartrita_kombinaciey_inyekcionnyh_form_hondroprotektorov/ (accessed 26.10.2020) (In Russ.).
Review
For citations:
Shavlovskaya O.A., Zolotovskaya I.A., Prokofyeva Yu.A. A new look at back pain treatment in light of the latest ESCEO guidelines. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(6):90-95. (In Russ.) https://doi.org/10.14412/2074-2711-2020-6-90-95
Views: 588
Email this article 